Published in J Chromatogr B Analyt Technol Biomed Life Sci on August 05, 2005
Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. Br J Pharmacol (2007) 0.93
Analytical and biological methods for probing the blood-brain barrier. Annu Rev Anal Chem (Palo Alto Calif) (2012) 0.86
Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG. Br J Pharmacol (2007) 0.85
The development of multiple probe microdialysis sampling in the stomach. J Pharm Biomed Anal (2008) 0.80
Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice. J Am Assoc Lab Anim Sci (2017) 0.75
Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages. J Clin Pharmacol (2014) 1.99
Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn (2008) 1.95
The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol (2010) 1.71
Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin Pharmacokinet (2011) 1.51
Disease system analysis: basic disease progression models in degenerative disease. Pharm Res (2005) 1.45
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn (2006) 1.35
Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet (2009) 1.34
Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2005) 1.33
What is the right dose for children? Br J Clin Pharmacol (2010) 1.24
Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet (2002) 1.23
Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther (2004) 1.12
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit (2009) 1.12
Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet (2012) 1.10
Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today (2008) 1.07
Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man. Pharm Res (2007) 1.05
Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther (2005) 1.05
Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res (2006) 1.04
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet (2009) 1.04
Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol (2011) 1.03
Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats. J Pharmacol Exp Ther (2007) 1.02
Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults. J Clin Pharmacol (2014) 1.02
A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res (2013) 1.00
Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol (2010) 1.00
Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions. Br J Clin Pharmacol (2013) 0.99
Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm (2011) 0.99
Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res (2010) 0.98
Evidence-based morphine dosing for postoperative neonates and infants. Clin Pharmacokinet (2014) 0.98
First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. J Pharmacokinet Pharmacodyn (2012) 0.97
Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation. Br J Clin Pharmacol (2013) 0.97
Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography. Epilepsia (2008) 0.96
Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet (2012) 0.96
Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. Br J Clin Pharmacol (2002) 0.96
Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn (2012) 0.96
Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol Blood Marrow Transplant (2012) 0.95
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res (2007) 0.95
Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations. Clin Pharmacokinet (2013) 0.95
A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res (2012) 0.94
Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet (2011) 0.94
Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol (2010) 0.94
Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol (2005) 0.94
Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol (2004) 0.94
Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. Clin Pharmacokinet (2010) 0.93
Coping with time scales in disease systems analysis: application to bone remodeling. J Pharmacokinet Pharmacodyn (2011) 0.93
Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet (2010) 0.93
Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology (2006) 0.93
Pharmacokinetics of clindamycin in pregnant women in the peripartum period. Antimicrob Agents Chemother (2010) 0.93
Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. Pharm Res (2012) 0.92
Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci (2011) 0.92
Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients. Eur J Clin Pharmacol (2007) 0.91
Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab Dispos (2011) 0.91
Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol (2014) 0.91
Predictive performance of a busulfan pharmacokinetic model in children and young adults. Ther Drug Monit (2012) 0.89
The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokinet Pharmacodyn (2013) 0.89
Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target (2004) 0.89
Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. Eur J Pharm Sci (2008) 0.88
Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J (2012) 0.88
Translation of drug effects from experimental models of neuropathic pain and analgesia to humans. Drug Discov Today (2012) 0.88
Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes. Am J Obstet Gynecol (2007) 0.87
Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.87
Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Investig (2013) 0.87
Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility. Schizophr Res (2013) 0.87
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology (2006) 0.86
Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin Pharmacol Ther (2002) 0.86
Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology (2006) 0.86
Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. J Pharmacol Exp Ther (2002) 0.86
Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. Ther Drug Monit (2012) 0.86
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats. Pharm Res (2011) 0.86
Ontogeny of hepatic glucuronidation; methods and results. Curr Drug Metab (2012) 0.85
Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology (2006) 0.85
Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. Br J Pharmacol (2006) 0.85
Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats. J Pharmacol Exp Ther (2004) 0.85
Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. J Pharmacol Exp Ther (2007) 0.85
Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography. Mol Imaging Biol (2006) 0.85
Functional role of adenosine receptor subtypes in the regulation of blood-brain barrier permeability: possible implications for the design of synthetic adenosine derivatives. Eur J Pharm Sci (2003) 0.84
In vitro iontophoresis of R-apomorphine across human stratum corneum. Structure-transport relationship of penetration enhancement. J Control Release (2002) 0.84
Low but inducible contribution of renal elimination to clearance of propylene glycol in preterm and term neonates. Ther Drug Monit (2014) 0.84
Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat. Epilepsia (2004) 0.84
Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. Clin Pharmacokinet (2011) 0.83
Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks. Antimicrob Agents Chemother (2007) 0.83
Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies. Eur J Pharm Sci (2006) 0.83
Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. Br J Clin Pharmacol (2002) 0.83
The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women. Br J Clin Pharmacol (2008) 0.83
Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials. Clin Pharmacokinet (2012) 0.83
The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments. J Pharmacol Toxicol Methods (2007) 0.82
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. J Pharmacol Exp Ther (2006) 0.82
Developmental pharmacokinetics of propylene glycol in preterm and term neonates. Br J Clin Pharmacol (2013) 0.82
Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat. Pharm Res (2007) 0.82
Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm Res (2004) 0.82
Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children. Br J Clin Pharmacol (2014) 0.82
Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res (2014) 0.82
Population pharmacokinetics of deferiprone in healthy subjects. Br J Clin Pharmacol (2014) 0.82
Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Eur J Pharm Sci (2005) 0.82
Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children. Br J Clin Pharmacol (2012) 0.82
Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. Am J Kidney Dis (2005) 0.82
Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors. Eur J Pain (2008) 0.81
Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients. Eur J Clin Pharmacol (2006) 0.81
Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. Clin Pharmacokinet (2007) 0.81
Application of a mechanism-based disease systems model for osteoporosis to clinical data. J Pharmacokinet Pharmacodyn (2013) 0.81
Impact of chronic inflammation on the pharmacokinetic-pharmacodynamic relationship of naproxen. Eur J Pain (2009) 0.81
Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020. Eur J Pharm Sci (2012) 0.81